Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: committee papers
Table of contents
01 Pre-meeting briefing
02 Company submission - Merck Sharp & Dohme
03 Company submission - risk analysis - Merck Sharp & Dohme
04 NICE clarification Letter
05 Company response to the NICE clarification letter
06 Company response to the NICE clarification letter – erratum
07 Professional group submission - NCRI/RCP/RCR/ACP and Melanoma Focus
08 Expert written personal statement - Louise Fearfield
09 Expert written personal statement - Pippa Corrie
10 Expert written personal statement - Gillian Nuttall
11 Expert written personal statement - Kathryn Silvester-Eccles
12 Evidence Review Group report
13 Evidence Review Group report – factual accuracy check
14 Erratum to the ERG report
Melanoma (unresectable, metastatic) - pembrolizumab (after ipilimumab) [ID760]: committee papers
07 September 2015 (7.98 Mb 39 sec) |
This page was last updated: 03 September 2015